[go: up one dir, main page]

NO934700L - Abrin varianter, abrin immunotoksiner og farmasoeytiske blandinger inneholdende disse - Google Patents

Abrin varianter, abrin immunotoksiner og farmasoeytiske blandinger inneholdende disse

Info

Publication number
NO934700L
NO934700L NO934700A NO934700A NO934700L NO 934700 L NO934700 L NO 934700L NO 934700 A NO934700 A NO 934700A NO 934700 A NO934700 A NO 934700A NO 934700 L NO934700 L NO 934700L
Authority
NO
Norway
Prior art keywords
abrin
immunotoxins
variants
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO934700A
Other languages
English (en)
Norwegian (no)
Other versions
NO934700D0 (no
Inventor
Aslak Godal
Original Assignee
Hafslund Nycomed As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hafslund Nycomed As filed Critical Hafslund Nycomed As
Publication of NO934700D0 publication Critical patent/NO934700D0/no
Publication of NO934700L publication Critical patent/NO934700L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42Lectins, e.g. concanavalin, phytohaemagglutinin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6821Plant heterodimeric toxins, e.g. abrin or modeccin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO934700A 1991-06-21 1993-12-20 Abrin varianter, abrin immunotoksiner og farmasoeytiske blandinger inneholdende disse NO934700L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113475A GB9113475D0 (en) 1991-06-21 1991-06-21 Chemical compound
PCT/EP1992/001419 WO1993000367A1 (fr) 1991-06-21 1992-06-20 Variantes d'abrine et immunotoxines

Publications (2)

Publication Number Publication Date
NO934700D0 NO934700D0 (no) 1993-12-20
NO934700L true NO934700L (no) 1993-12-20

Family

ID=10697123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934700A NO934700L (no) 1991-06-21 1993-12-20 Abrin varianter, abrin immunotoksiner og farmasoeytiske blandinger inneholdende disse

Country Status (5)

Country Link
EP (1) EP0590011A1 (fr)
JP (1) JPH06510525A (fr)
GB (1) GB9113475D0 (fr)
NO (1) NO934700L (fr)
WO (1) WO1993000367A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002174A1 (fr) * 1992-07-28 1994-02-03 Toray Industries, Inc. Immunocomplexe
KR20090073255A (ko) * 2006-10-27 2009-07-02 트르스티스 오브 보스톤 유니버시티 질병, 악성 종양 및 장애를 치료하기 위한 표적화 분열 생체 분자성 접합체, 및 그의 생성 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2575160B1 (fr) * 1984-12-21 1987-03-20 Sanofi Sa Composes ionophores carboxyliques monovalents
JPH02502251A (ja) * 1987-11-13 1990-07-26 ヘルマン カーティンガー ヒトのモノクローン性抗hiv‐1‐抗体

Also Published As

Publication number Publication date
EP0590011A1 (fr) 1994-04-06
NO934700D0 (no) 1993-12-20
WO1993000367A1 (fr) 1993-01-07
GB9113475D0 (en) 1991-08-07
JPH06510525A (ja) 1994-11-24

Similar Documents

Publication Publication Date Title
GB2376464B (en) Processes and apparatus for extraction of active substances and enriched extracts from natural products
DK0569505T3 (da) 3-Difluormethylpyrazolcarboxamidfungicider
DK472184D0 (da) 2-amino-5-hydroxy-4-methylpyrimidin-derivater og farmeceutiske praeparater indeholdende disse
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
AU2255388A (en) Substrate for plants and its use
NO864971D0 (no) Monoklonale antistoffer som er kryssreaktive og kryssbeskyttende overfor p. aeruginosa serotyper.
DK93685D0 (da) Benzisoselenazolthioner, fremgangsmaade til fremstilling af disse forbindelser og farmaceutiske praeparater indeholdende disse forbindelser
MX154815A (es) Mejoras en planta compresora
ES2195040T3 (es) Conjugado que incluye un principio activo, un polipeptido y varios polieteres y su uso como medicamento.
NL960011I1 (nl) Carrageenan bevattende farmaceutische samenstellingen.
NO934700L (no) Abrin varianter, abrin immunotoksiner og farmasoeytiske blandinger inneholdende disse
ES483662A1 (es) Un procedimiento para la produccion de una 2-aminoetil-1-fe-nilindolina
IT1171152B (it) Impianto per l estrazione di gas in quinanti da ambienti chiusi
NO802657L (no) Melamin som nitrogenkilde i plantegjoedning
MD232C2 (ro) Mediu pentru cultivarea microorganismelor Campylobacter jejuni/coli
JPS51125736A (en) An insecticide for agriculture and gardening
ES2113647T3 (es) Composicion.
IT7904835A0 (it) Accumulatore doppio, per esempio per applicazione in impianti di osmosi invertita ed altri impianti idrotecnici.
DK0703916T3 (da) 14-Substituerede marcfortiner og derivater, der kan anvendes som antispirant-midler
DK0667747T3 (da) Fødevareprodukt i pulverform og fremgangsmåde til dets fremstilling
JPS51125750A (en) Agermicide for agricuture and gardening
FR2686019B1 (fr) Composition de seve et d'extrait vegetal.
IT1125547B (it) Impianto per la produzione di metano da liquami in genere e simili
DK0625351T3 (da) Anvendelse af etofibrat og farmaceutiske præparater indeholdende etofibrat til behandling af diabetisk angio- og retinopati
JPS54107589A (en) Separation and purification of staphylokinase